A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of SLS-002
(intranasal racemic ketamine) in addition to standard of care on symptoms of Major Depressive
Disorder (MDD) and suicidality, in participants who are assessed to be at imminent risk for
suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating
Scale (MADRS) total score at 24 hours post first dose.